Australia, April 10 -- IMMUDEX Aps, owns the trademark (2616030) for 'Xynapse' till Oct. 14, 2035.

Status: protected: Registered/protected

Classes: 1 [Chemical products for diagnostic (non-medical), industrial and scientific purposes; diagnostic reagents for diagnostic (not for medical or veterinary) and scientific purposes; research reagents for scientific and diagnostic purposes; diagnostic test materials for scientific and diagnostic purposes (not for medical or veterinary purposes); diagnostic kits for scientific and diagnostic purposes (not for medical or veterinary purposes); test kits for research and diagnostic purposes (not for medical or veterinary purposes); biochemical reagents (not for medical or veterinary purposes); analytical preparations for scientific purposes related to vaccines and immunotherapeutics, cancer vaccines, borrelia vaccines, tuberculosis vaccines, HIV vaccines, CMV vaccines and other vaccines, or for use in connection with therapy and immunotherapy, including cancer therapy, cancer immunotherapy, for analysis or treatment of T-cell lymphoma, T-cell infiltration of solid tumors and tissues, and for analysis of infectious diseases and autoimmunity, and for use in connection with toxicological studies, transplantation, immune monitoring, or vaccines and T-cell monitoring; chemical reagents, other than for medical or veterinary purposes.] and 5 [Preparations for pharmaceutical purposes, preparations for medical purposes, chemical-pharmaceutical preparations, diagnostic preparations for medical purposes, reagents for medical and veterinary purposes; vaccines; analytical preparations for medical purposes, including for each of the above preparations for the development or analysis of vaccines, immunotherapeutics and cellular therapy, including cancer vaccines and immunotherapeutics, borrelia vaccines, tuberculosis vaccines, HIV vaccines and CMV vaccines, T-cell treatments, or for use in connection with cancer therapy or other therapy, for the analysis or treatment of T-cell lymphoma, T-cell infiltration of solid tumors and tissues, and infectious diseases, and for use in connection with toxicological studies, transplantation, immune monitoring, or vaccines and T-cell monitoring.]

Type of Mark: Word

Date of Acceptance: Jan. 31

Registration Advertised: April 9

For further details contact FB Rice Pty. Ltd. and AWA Denmark A.S .

The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2616030.

Disclaimer: Curated by HT Syndication.